Results 51 to 60 of about 2,834,658 (290)

Species-specific activity of antibacterial drug combinations [PDF]

, 2018
The spread of antimicrobial resistance has become a serious public health concern, making once-treatable diseases deadly again and undermining the achievements of modern medicine1,2.
André Mateus, Banzhaf, Manuel; id_orcid, Ezraty, Benjamin, Anja Telzerow, Zietek, M., Py, B., Foerster, S., Joel Selkrig, Py, Béatrice, Huth, E., Telzerow, Anja, Selkrig, J., Emily Huth, Typas, Athanasios, Ana Rita Brochado, Sunniva Foerster, Natalie Ng, Stephan Göttig, Benjamin Ezraty, Savitski, Mikhail, Jordi Zamarreño Beas, Béatrice Py, Förster, Sunniva, Telzerow, A., Brochado, Ana Rita, Ng, N., Athanasios Typas, Göttig, S., Zietek, Matylda, Matylda Zietek, Ng, Natalie, Barras, Frédéric, Peer Bork, Savitski, M.M., Bork, Peer, Selkrig, Joel, Bobonis, J., Jacob Bobonis, Typas, A., Manuel Banzhaf, Zamarreño Beas, J., Bork, P., Bassler, Stefan, Göttig, Stephan, Stefan Bassler, Mateus, André, Banzhaf, Manuel, Mikhail M. Savitski, Brochado, A.R., Zamarreño Beas, Jordi, Bassler, S., Bobonis, Jacob, Ezraty, B., Huth, Emily, Barras, F., Banzhaf, M., Mateus, A., Frédéric Barras, Foerster, Sunniva, Savitski, Mikhail M, Zamarreño Beas J, Zietek M, Banzhaf M, Göttig S, Bobonis J, Py B, Bassler S, Foerster S, Huth E, Savitski MM, Mateus A, Ezraty B, Selkrig J, Ng N, Typas A, Brochado AR, Bork P, Telzerow A, Barras F   +78 more
core   +2 more sources

Effective drug combinations in breast, colon and pancreatic cancer cells. [PDF]

, 2022
Combinations of anti-cancer drugs can overcome resistance and provide new treatments1,2. The number of possible drug combinations vastly exceeds what could be tested clinically.

core   +2 more sources

Retrospective Analysis of Donor Lymphocyte Infusions in Pediatric Patients With Mixed Chimerism After Hematopoietic Stem Cell Transplantation

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an essential therapy for several malignant and nonmalignant diseases, but relapse and graft loss remain the principal threats to its success. Routine monitoring of chimerism and minimal residual disease (MRD) enables early detection of imminent recurrence and guides ...
Carmen Junk, Sebastian Michaelis, Michaela Döring, Thomas Eichholz, Ursula Holzer, Martin Ebinger, Tim Flaadt, Rupert Handgretinger, Peter Lang, Jan Frederic Weller, Markus Mezger   +10 more
wiley   +1 more source

Drug-drug combination map.

, 2019
Fig 2 depicts the pairwise drug-drug combinations extracted from phase III and IV ovarian cancer clinical trials of the 43 drugs used in these combinations.
Michael Schwarz (209306), Andreas Heinzel (610394), Michael Krainer (42689), Paul Perco (32894), Paul Mayer (611308), Arno Lukas (32895), Maximilian Marhold (3764131), Erwin Tomasich (3764128)   +7 more
core   +1 more source

PINet 1.0: A pathway network-based evaluation of drug combinations for the management of specific diseases

Frontiers in Molecular Biosciences, 2022
Drug combinations can increase the therapeutic effect by reducing the level of toxicity and the occurrence of drug resistance. Therefore, several drug combinations are often used in the management of complex diseases.
Yongkai Hong, Dantian Chen, Yaqing Jin, Mian Zu, Yin Zhang   +4 more
doaj   +1 more source

The synergistic drug combinations of Epirubicin and Sorafenib.

, 2022
The synergistic drug combinations of Epirubicin and Sorafenib.
Richard A. McIndoe (12354721), Hongyan Xu (29047), Jiaqi Li (220961)   +2 more
core   +1 more source

Pediatric Idiopathic Multicentric Castleman Disease Is Often Severe But Responsive to Siltuximab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin‐6 (IL‐6) inhibitor, is the only FDA‐approved treatment for adult patients with iMCD.
Bridget Austin, Sheila K. Pierson, Kelley C. Dacus, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Larissa Borys, Kayla McHugh, Abiola Irvine, Yoojin Jo, Adam Bagg, Mary Jo Lechowicz, Daisy Alapat, Amy Chadburn, Megan S. Lim, Gordan Srkalovic, Frits van Rhee, David C. Fajgenbaum, Joshua D. Brandstadter   +17 more
wiley   +1 more source

The processes of reform in Victoria’s alcohol and other drug sector, 2011-2014 [PDF]

, 2014
This paper explores issues and concerns related to the 2014 alcohol and other drug sector recommissioning process in Victoria. Overview In mid-2014, the Victorian Alcohol and Drug Association approached the Drug Policy Modelling Program, at the ...
Drug Policy Modelling Program
core  

Venetoclax‐Based Therapy as a Bridge to Hematopoietic Stem Cell Transplantation in Relapsed or Refractory Pediatric Acute Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Relapsed and/or refractory (R/R) pediatric acute leukemia carries a dismal prognosis, largely driven by chemoresistance to conventional salvage therapy. The BH3‐mimetic venetoclax, combined with chemotherapy or hypomethylating agents, has demonstrated efficacy in small clinical trials.
Katherine S. Colman, Deborah Meyran, Vajiranee Malalasekera, Heather Weerdenburg, Janine Campbell, Rachel Conyers, Stacie Wang, Hannah Walker, Seong Lin Khaw, Diane Hanna   +9 more
wiley   +1 more source

A comprehensive review of cluster methods for drug–drug interaction network

Quantitative Biology
The detection of drug–drug interaction (DDI) is crucial to the rational use of drug combinations. Experimentally, DDI detection is time‐consuming and laborious.
Shuyuan Cao, Guixia Liu, Xiangrun Zhou, Ji Lv   +3 more
doaj   +1 more source